Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class III drug recalls - low risk

Class III means the product is unlikely to cause harm but violates FDA labeling or manufacturing rules. These are the recalls you rarely hear about; pharmacies usually just swap the affected lot.

1,716 recalls, newest first.

Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0536-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Golden State Medical Supply Inc. NDC 51407-638-01 D-0535-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Golden State Medical Supply Inc. NDC 51407-637-05 D-0534-2026
Class III · Low risk

Primidone Tablets USP

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Lannett Company Inc. NDC 0527-1231-01 D-0533-2026
Class III · Low risk

Premier

Labeling: Incorrect or Missing Lot and/or Exp Date:The expiration date has an extra digit and is printed as 2709114 instead of the correct 270914 (2027-09-14). It is important to note that this error is limited to the vial itself; the saleable unit of the box of 12 bottles has the correct expiration date printed.

Ongoing Labeling / mix-up Premier Dental Products Co NDC 48783-112-08 D-0490-2026
Class III · Low risk

Skin Rehab

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-04 D-0481-2026
Class III · Low risk

Remedy Gel

Subpotent Drug

Terminated Wrong potency / content Island Kinetics, Inc. d.b.a. CoValence Laboratories NDC 66915-531-12 D-0480-2026
Class III · Low risk

Nilotinib Capsules

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Ongoing Failed specification Cipla USA, Inc. NDC 69097-032-74 D-0382-2026
Class III · Low risk

Nilotinib Capsules

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Ongoing Failed specification Cipla USA, Inc. NDC 69097-031-74 D-0381-2026
Class III · Low risk

Eptifibatide Injection

Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 mg/100 mL vial for weight-adjusted bolus dosing. The approved statement is 75 mg/100 mL vial for weight-adjusted infusion.

Ongoing Labeling / mix-up Slate Run Pharmaceuticals D-0343-2026
Class III · Low risk

Pitavastatin Tablets

Presence of foreign tablets/capsules: one Pitavastatin tablet 1mg found in bottle of Pitavastatin tablets 2mg

Ongoing Particulate / foreign matter Annora Pharma Private Limited NDC 72603-479-01 D-0391-2026
Class III · Low risk

Doxazosin Tablets

Tablets/Capsules Imprinted with Wrong ID

Ongoing Labeling / mix-up Unichem Pharmaceuticals USA Inc. NDC 29300-353-10 D-0306-2026
Class III · Low risk

parodontax

Labeling: Incorrect or Missing Lot and/or Exp Date: Potential for missing or illegible lot and expiration date coding on the bottles.

Ongoing Labeling / mix-up Haleon US Holdings LLC NDC 0135-0651-02 D-0297-2026
Class III · Low risk

traZODONE Hydrochloride Tablets

Failed Tablet/Capsule Specifications: Product complaint received that some tablets had a dent on the plain side of the tablet surface.

Ongoing Failed specification Zydus Pharmaceuticals (USA) Inc NDC 68382-806-10 D-0247-2026
Class III · Low risk

Fesoterodine Fumarate

Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

Ongoing Impurity / degradation Alembic Pharmaceuticals Limited NDC 62332-176-30 D-0248-2026
Class III · Low risk

Clindamycin Phosphate USP

Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.

Ongoing Impurity / degradation Sun Pharmaceutical Industries INC NDC 51672-4081-4 D-0257-2026

Recalls by year